Open AccessThe Potential of Amniotic Fluid-Derived Extracellular Vesicles to Treat Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus Hydroxychloroquine in Human Patients
Author(s) -
Ian White
Publication year - 2020
Publication title -
epidemiology
Language(s) - English
Resource type - Journals
ISSN - 2473-4780
DOI - 10.17140/epoj-5-118
Subject(s) - hydroxychloroquine , medicine , coronavirus , rheumatoid arthritis , pandemic , amniotic fluid , chloroquine , covid-19 , intensive care medicine , immunology , virology , disease , pregnancy , malaria , infectious disease (medical specialty) , biology , fetus , genetics
Recently a lot of attention has been focused on fast-tracking repurposed drugs for the treatment of a novel coronavirus; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent leading to the devastating coronavirus disease-2019 (Covid-19). One of the first and most well-known examples is hydroxychloroquine (HCQ), which has been used for years as a treatment for malaria, rheumatoid arthritis and lupus. HCQ was rolled out as a miracle treatment for Covid-19, which was inexpensive, effective and causing few side-effects. However, its effectiveness in treating Covid-19 has recently been questioned leaving doctors and patients confused and desperate. Here the proposed mechanisms of action of HCQ are discussed and compared with an inexpensive, safe and effective alternative, which is derived from natural, healthy amniotic fluid.